• Celltrion, iProgen Biotech to develop a series of novel ADCs biospectrumasia
    April 09, 2019
    The deal aims to co-develop up to 4 ADCs including a novel ADC (Antibody-drug conjugate) that targets breast cancers expressing low levels of HER2 using iProgen’s proprietary antibody drug delivery technology.
PharmaSources Customer Service